Turkish Validity and Reliability of the Core Lower Urinary Tract Symptoms Questionnaire in Individuals With Multiple Sclerosis
Turkish Validity and Reliability of the Core Lower Urinary Tract Symptoms Questionnaire in Patients With Multiple Sclerosis
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Center
-
Kütahya, Center, Turkey (Türkiye)
- Kutahya Health Sciences University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Being between 18-65 years old
- Being diagnosed with multiple sclerosis by a specialist
- Being willing to participate in the study
- Being literate
Exclusion Criteria:
- Not volunteering to participate in the study
- Having a neurological disorder that prevents speech
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Multiple Sclerosis Group
Individuals between the ages of 18-65 who have been diagnosed with multiple sclerosis by a specialist physician.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Core Lower Urinary Tract Symptoms Score
Time Frame: 10 minuttes
|
The questionnaire was developed by Homma et al. in 2008 to assess lower urinary tract symptoms.
The Turkish validity and reliability study of the questionnaire was conducted by Erbay et al. in 2022.
The first 5 questions in the 13-question questionnaire are about storage problems, the next 3 questions are about urination problems, and the next 2 questions are about lower urinary tract pain.
The first 10 questions are scored on a Likert-type scale from 0 to 3. The Core Lower Urinary Tract also includes a question asking participants to list three core symptoms (question 11) and a question about the primary core symptom (question 12).
It also includes a question about quality of life (question 13).
The last question is about the patients' satisfaction with their current urinary status, scored from 0 to 6.
|
10 minuttes
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overactive Bladder Questionnaire-V8
Time Frame: 5 minutes
|
Overactive Bladder Questionnaire was first developed in English by Coyne and colleagues in 2002.
In later studies, Overactive Bladder Questionnaire short form and shorter forms such as Overactive Bladder Questionnaire-V8 were developed.
Overactive Bladder Questionnaire-V8 consists of the first 8 questions of Overactive Bladder Questionnaire and was recommended as an Overactive Bladder Questionnaire screening and awareness test.
The validity and reliability of the questionnaire in Turkish was conducted by Tarcan et al. in 2012.
Today, it is frequently used to evaluate lower urinary tract symptoms.
The Overactive Bladder Questionnaire-V8 uses a Likert-type scale of 0-5 to determine the severity of individuals' complaints: None (0); a little (1); a little (2); a lot (3); a lot (4); a lot (5).
The total score is between 0 and 40.
If the total score obtained from the questionnaire is more than 8, individuals are considered to have possible lower urinary tract symptoms.
|
5 minutes
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Autoimmune Diseases
- Immune System Diseases
- Urological Manifestations
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Multiple Sclerosis
- Lower Urinary Tract Symptoms
Other Study ID Numbers
Other Study ID Numbers
- 2024/04-13
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.